Mucosal immunisation and adjuvants: A brief overview of recent advances and challenges

Vaccine

Volumn 21, Issue SUPPL. 2, 2003, Pages

  Holmgren, Jan ^a   Czerkinsky, Cecil ^b   Eriksson, Kristina ^a   Mharandi, Ali ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INSERM   (France)

Author keywords

Anti infectious vaccines; Innate immunity; Oral tolerance

Indexed keywords

ANTIGEN; BACTERIAL DNA; BACTERIAL TOXIN; BCG VACCINE; CHEMOKINE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; DNA VACCINE; ENTEROTOXIN; ENVELOPE PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; LIVE VACCINE; OLIGONUCLEOTIDE; OVALBUMIN; POLIOMYELITIS VACCINE; PROTEIN A; RANTES; ROTAVIRUS VACCINE; TETANUS TOXOID; TYPHOID VACCINE; UNINDEXED DRUG; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTHRITIS; AUTOIMMUNE DISEASE; CHOLERA; CLINICAL TRIAL; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FACIAL NERVE PARALYSIS; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; INTUSSUSCEPTION; LEISHMANIA MAJOR; LIVER GRANULOMA; MICROBIAL IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN MOTIF; PROTOZOAL INFECTION; REVIEW; SCHISTOSOMA MANSONI; SIDE EFFECT; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; TREMATODIASIS; TUBERCULOSIS; UVEITIS; VIRUS INFECTION; VIRUS PARTICLE;

EID: 0038325751     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00206-8     Document Type: Review

References (41)

1. Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR. Mucosal immunology. 2nd ed. San Diego: Academic Press; 1999.
2. Belyakov I.M., Moss B., Strober W., Berzofsky J.A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U.S.A. 96:1999;4512-4517.
3. Eriksson K., Kilander A., Hagberg L., Norkrans G., Holmgren J., Czerkinsky C. Induction and expression of intestinal humoral immunity in HIV-infected individuals: prospects for vaccination against secondary enteric infections. Pathobiology. 66:1998;176-182.
4. Faria A.M., Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73:1999;153-264.
5. Murphy T.V., Gargiullo P.M., Massoudi M.S.et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344:2001;564-572.
6. Lang D. Safety evaluation of toxin adjuvants delivered intranasally. http://www.niaid.nih.gov/dmid/enteric/intranasal.htm.
7. Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
8. Choy E.H., Scott D.L., Kingsley G.H.et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44:2001;1993-1997.
9. de Haan L., Hirst T.R. Cholera toxin and related enterotoxins: a cell biological and immunological perspective. J. Nat. Toxins. 9:2000;281-297.
10. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector system. Vaccine. 11:1993;1179-1184.
11. Lycke N. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:1997;504-520.
12. Gagliardi M., Sallusto F., Marinaro M., Vendetti S., Riccomi A., De Magistris M. Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses. Int. J. Med. Microbiol. 291:2002;571-575.
13. Eriksson K., Fredriksson M., Nordström I., Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1/Th2 development. Infect. Immun. 71:2003;1740-1747.
14. Staats H.F., Ennis F.A. Jr. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol. 162:1999;6141-6147.
15. de Haan L., Verweij W., Holtrop M.et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine. 19:2001;2898-2907.
16. George-Chandy A., Eriksson K., Lebens M., Nordström I., Schon E., Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect. Immun. 69:2001;5716-5725.
17. Pizza M., Giuliani M., Fontana M.et al. Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 19:2001;2534-2541.
18. Mowat A.M., Donachie A.M., Jagewall S.et al. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 167:2001;3398-3405. [This article reports the adjuvant activity of oral administration of CTA1-DD when given together with ISCOMs].
19. Sanchez J., Wallerstrom G., Fredriksson M., Angstrom J., Holmgren J. Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J. Biol. Chem. 277:2002;33369-33377. [This paper is the first description of a new strategy to induce detoxification of cholera toxin].
20. Medzhitov R., Janeway C. Jr. The toll receptor family and microbial recognition. Trends Microbiol. 8:2000;452-456.
21. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760. [This is an up-to-date review of immune effects of bacterial CpG DNA, mechanisms of action and the therapeutic applications of CpG DNA].
22. McCluskie M.J., Weeratna R.D., Krieg A.M., Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 19:2000;950-957.
23. Gallichan W., Woolstencroft R., Guarasci T., McCluskie M., Davis H., Rosenthal K. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:2001;3451-3457.
24. Harandi A.M., Eriksson K., Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J. Virol. 77:2003;953-962. [This is the first report on induction of strong mucosal innate immune response in the female genital tract mucosa by using CpG DNA. This article also documents the protective role of vaginally administered CpG DNA against genital herpes infection].
25. Staats H.F., Bradney C.P., Gwinn W.M.et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167:2001;5386-5394.
26. Eo S.K., Lee S., Kumaragur U., Rouse B.T. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine. 19:2001;4685-4693.
27. Lilliard J.W.J., Boyaka P.N., Taub D.D., McGhee J.R. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol. 166:2001;162-169.
28. Niikura M., Takamura S., Kim G.et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology. 293:2002;273-280.
29. Guerrero R.A., Ball J.M., Krater S.S., Pacheco S.E., Clemens J.D., Estes M.K. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75:2001;9713-9722.
30. Shi W., Liu J., Huang Y., Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T lymphocyte responses. J. Virol. 75:2001;10139-10148.
31. Gardner J.P., Frolov I., Perri S.et al. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 74:2000;11849-11857.
32. Vajdy M., Gardner J., Neidleman J.et al. Human immunodeficiency virus type 1 gag-specific vaginal immunity and protection after local immunizations with Sindbis virus-based replicon particles. J. Infect. Dis. 184:2001;1613-1616.
33. Bergerot I., Ploix C., Petersen J. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 94:1997;4610-4614.
34. Tarkowski A., Sun J.-B., Holmdahl R., Holmgren J., Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum. 42:1999;1628-1634.
35. Sun J.-B., Xiao B.-G., Lindblad M.et al. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression. Int. Immunol. 12:2000;1449-1457.
36. Rask C., Holmgren J., Fredriksson M.et al. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. Clin. Exp. Allergy. 30:2000;1024-1032.
37. Boirivant M., Fuss U., Ferroni L., De Pascale M., Strober W. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J. Immunol. 166:2001;3522-3532.
38. Sun J.-B., Stadecker M.J., Mielcarek N.et al. Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoni-infected mice. Scand. J. Immunol. 54:2001;440-447.
39. Lebens M., Sun J.-B., Sadeghi H.et al. A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine. 21:2003;514-520.
40. McSorley S.J., Rask C., Pichot R., Julia V., Czerkinsky C., Glaichenhaus N. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur. J. Immunol. 28:1998;424-432.
41. Phipps P.A., Stanford M.R., Sun J.-B.et al. Prevention of mucosally induced uveitis with a HSP60 derived peptide linked to cholera toxin B subunit. Eur. J. Immunol. 33:2003;224-232.